ArticleGut microbes2020
Specific gut microbiome signature predicts the early-stage lung cancer.
Article in Gut microbes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
180 citing papers in PubMed, 3 syntheses or guidelines pooled it, 284 citations in OpenAlex.
- A Risk Score for Polycystic Ovary Syndrome Based on Meta-Analysis and Machine Learning of Gut Microbiota Signatures.Reproductive sciences (Thousand Oaks, Calif.) · 2026Pooled it
- The composition alteration of gut microbiota in lung cancer: a systematic review and meta-analysis.Frontiers in microbiology · 2026Pooled it
- The Intriguing Connection Between the Gut and Lung Microbiomes.Pathogens (Basel, Switzerland) · 2024Pooled it
- Dysbiosis in the Gut Microbiome of Pembrolizumab-Treated Non-Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic Sampling.Thoracic cancer · 2025Trial
- Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.Gut microbes · 2026Review
- Intratumoral microbiota in the growth of CRC and lung cancer: Comprehensive insights from etiology to therapy.iScience · 2026Review
- The Oral and Nasal Gateway Microbiomes: Salivaomics and Systemic Health at the Airway-Digestive Interface.Microorganisms · 2026Review
- The Gut-Lung Microbiome Axis in Alveolar Stem Cell Regeneration and Lung Repair.Microorganisms · 2026Review
- Microbial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut-Lung-Immune Axis.Cancers · 2026Review
- Salivary Metabolic Characteristics and Response to Neoadjuvant Systemic Therapy in Breast Cancer.International journal of molecular sciences · 2026Article
- Exploring the characteristics of gut microbiome changes in lung cancer patients and healthy controls.Scientific reports · 2026Article
- Causal relationship between GM, immune cells and esophageal adenocarcinoma: a mediation analysis based on MR.Journal of cardiothoracic surgery · 2026Article
- 16S rRNA gene sequencing reveals distinct intratumoral bacterial microbiome signatures between CT indeterminate benign and early-stage malignant pulmonary lesions.Journal of translational medicine · 2026Article
- The Dynamic Gut Microbiota: Monitoring Alterations During Lung Cancer Progression for Diagnosis and Precision Medicine.International journal of molecular sciences · 2026Review
- Evaluation of the ALIBIRD mHealth Platform for Care of Patients With Lung Cancer: Prospective Pilot Study.JMIR cancer · 2026Article
- Microflora: a promising potential in the diagnosis and treatment of non-small cell lung cancer.International journal of clinical oncology · 2026Review
- Superparamagnetic iron oxide nanoparticle restores gut microbiota homeostasis to enhance lung cancer immunotherapy.National science review · 2026Article
- Modulatory role of Akkermansia muciniphila in cancer pathophysiology: a systematic review and meta-analysis of preclinical studies.Gut pathogens · 2026Review
- Association between the oral microbiome and clinical indicators of resectable non-small cell lung cancer (NSCLC).Journal of oral microbiology · 2026Article
- Preoperative gut microbiota combined with machine learning for predicting post-hepatectomy liver failure in HBV-related hepatocellular carcinoma: a pilot study.Frontiers in cellular and infection microbiology · 2026Article
120 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations of gut microbiota have been implicated in multiple diseases including cancer. However, the gut microbiota spectrum in lung cancer remains largely unknown. Here we profiled the gut microbiota composition in a discovery cohort containing 42 early-stage lung cancer patients and 65 healthy individuals through the 16S ribosomal RNA (rRNA) gene sequencing analysis. We found that lung cancer patients displayed a significant shift of microbiota composition in contrast to the healthy populations. To identify the optimal microbiota signature for noninvasive diagnosis purpose, we took advantage of Support-Vector Machine (SVM) and found that the predictive model with 13 operational taxonomic unit (OTU)-based biomarkers achieved a high accuracy in lung cancer prediction (area under curve, AUC = 97.6%). This signature performed reasonably well in the validation cohort (AUC = 76.4%), which contained 34 lung cancer patients and 40 healthy individuals. To facilitate potential clinical practice, we further constructed a 'patient discrimination index' (PDI), which largely retained the prediction efficiency in both the discovery cohort (AUC = 92.4%) and the validation cohort (AUC = 67.7%). Together, our study uncovered the microbiota spectrum of lung cancer patients and established the specific gut microbial signature for the potential prediction of the early-stage lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.